// App-Quantinova.ai

5002 : [68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC A VISION substudy.

Researchers

Presenter

  • Phillip Kuo

Principal Investigators

  • Jacob Hesterman

  • Kambiz Rahbar

  • Ayse T. Kendi

  • Xiao X. Wei

  • Bruno Fang

  • Nabil Adra

  • Andrew J. Armstrong

  • Rohan Garje

  • Jeff M. Michalski

  • Samson Ghebremariam

  • Marcia Brackman

  • Connie Wong

  • Taylor Benson

  • Nicholas J. Vogelzang

Medical Centers

  • University of Arizona, Tucson, AZ

  • Invicro, Needham, MD

  • Universitatsklinikum Munster, Munster, Germany

  • Mayo Clinic, Rochester, MN

  • Dana-Farber Cancer Institute, Boston, MA

  • Astera Cancer Care, East Brunswick, NJ

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC

  • University of Iowa, Iowa City, IA

  • Washington University in St Louis, St. Louis, MO

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis Pharmaceuticals Corporation, Indianapolis, IN

  • Novartis Pharmaceutical Corporation, Cambridge, United Kingdom

  • Novartis Pharmaceuticals Corporation, St George, UT

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

Locations

  • United States

  • Germany

  • United Kingdom

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved